A significant analyst price target hike for Quantum Computing Inc. (QUBT) fuels a massive rally in the leveraged ETF.
Regulators expedite review for ALTO-101, a novel treatment for cognitive impairment in schizophrenia, a condition with no currently approved therapies.
Shares surge over 76% as the company secures Nevada Tech Hub funding and a key U.S. patent for its charging technology.
Health insurer's stock rallies as it maintains financial targets despite recent Medicare Star Ratings challenges.
Singapore-based security firm Concorde International Group sees massive trading volume without any apparent news catalyst, prompting investor caution.
Government award will advance the company's non-vaccine influenza therapeutic, CD388, and onshore its manufacturing ahead of a potential pandemic.
Regulators expedite review for ALTO-101, targeting a key aspect of schizophrenia with no currently approved treatments.
Internal U.S. Army memo flags 'fundamental security' vulnerabilities in a key battlefield communications network, raising contract concerns.